AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02775084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 4 capsules twice daily with food for 6 weeks
Study NCT00609193 — intervention group
Intervention type: DRUG
Intervention: lithium
Description: standard clinical care
Study NCT00609193 — intervention group
Intervention type: DRUG
Intervention: quetiapine
Description: standard clinical care
Study NCT02330575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
Study NCT02330575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
Study NCT02330575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
Study NCT01231659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10 mg (2 tablets of 5 mg) once daily
Study NCT01231659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg once daily
Study NCT01314963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype intraoperative handheld gamma camera (pIHGC)
Description: The prototype intraoperative handheld gamma camera (pIHGC) consists of a parallel-hole lead collimator coupled to a pixilated sodium iodide-thallium \[NaI(Tl)\] scintillation crystal array, itself coupled to a flat panel, multi-anode Hamamatsu H8500 position-sensitive photomultiplier tube. The collimator is 5x5 cm2 large in area and 1.5 cm thick, with 1.3 mm hexagonal holes and 0.2 mm septa. The 1.7 mm pitch crystal array is composed of 29x29 individual crystals, each 1.5x1.5x6 mm3 in size.
Study NCT01314963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoscintigraphy with intraoperative gamma probes (GP)
Description: Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)
Study NCT01314963 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radioactive Tc99M
Description: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
Study NCT01314963 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radioactive Tc99M
Description: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.
Study NCT02386748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing gum
Description: Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
Study NCT02386748 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral fluids
Description: Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
Study NCT02386748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
Study NCT02386748 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
Study NCT02386748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fluids
Description: Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
Study NCT03331861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: Metformin starting at 500mg twice a day and increasing to 1000mg twice a day for a total of 6 months
Study NCT03331861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar dosing regime as active comparator
Study NCT03250260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-dimensional photograph with simulation
Description: The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
Study NCT03250260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Viewing of a 2-dimensional photographic library
Description: The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
Study NCT00113074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Nicotine replacement therapy program
Study NCT00113074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy
Description: Nicotine replacement therapy program
Study NCT00113074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Diet program
Study NCT00113074 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Diet program
Study NCT04091490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination of 2 cycles of Nivolumab as a monotherapy with 4 cycles of high-dose chemotherapy (DHAP chemoregimen) with Nivolumab
Study NCT03800784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
Study NCT01578408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Study NCT01578408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Lubinus SPII stem (control arm)
Description: Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
Study NCT01578408 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented HA Coated Corail stem
Description: Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
Study NCT00038727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPPOS Group Lifestyle
Description: Quarterly group lifestyle sessions
Study NCT00038727 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: DPPOS Group Lifestyle
Description: Quarterly group lifestyle sessions
Study NCT00038727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Administered as 850mg twice per day, masked in DPP and open label in DPPOS
Study NCT00038727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPPOS Boost Lifestyle
Description: In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
Study NCT00038727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Lifestyle Group Session
Description: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions
Study NCT00038727 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Intensive Lifestyle Group Session
Description: 16 session curriculum in group format. In DPP delivered to ILS as individual sessions
Study NCT03590730 — intervention group
Intervention type: DEVICE
Intervention: ICD implantation
Description: ICD will be implanted according to current guidelines recommendations.
Study NCT02667210 — intervention group
Intervention type: OTHER
Intervention: Medical Record Review
Description: Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
Study NCT03846986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Apple Juice1
Description: Apple Juice1
Study NCT03846986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple Juice2
Description: 100% Apple Juice with enzyme-treated apple pomace fiber
Study NCT03846986 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Raw Apple
Description: Raw Apple
Study NCT00509067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
Study NCT00509067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP-choline
Description: CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
Study NCT00509067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
Study NCT00509067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
Study NCT00509067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Description: All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
Study NCT00574288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Daratumumab
Description: First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
Study NCT00574288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Daratumumab
Description: In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
Study NCT00574288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.~Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions.
Study NCT00574288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
Study NCT04243850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Jardiance
Study NCT04243850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Jardiance
Study NCT04243850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo
Study NCT04243850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT04243850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
Study NCT04243850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: caffeine iv to investigate wheter the changes in renal hemodynamics are adenosine dependent
Study NCT02772640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin and Ezetimibe morning or evening administration
Description: Timing of the drug administration:~morning -> evening evening -> morning
Study NCT03963414 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab in combination with carboplatin and etoposide
Description: 1500mg of durvalumab plus 75mg of tremelimumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4. 1500mg of durvalumab plus 75mg of tremelimumab will be given every 3 weeks for Cycles 5 and 6.
Study NCT03963414 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with carboplatin and etoposide
Description: 1500mg of durvalumab in combination with carboplatin and etoposide will be given every 3 weeks for Cycles 3 and 4.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Pediatric transplant subject with d-AIH
Description: 30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Pediatric transplant subject with acute rejection
Description: Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Pediatric transplant subject with chronic rejection
Description: Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Adult non-transplant patients with auto-immune hepatitis
Description: 75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.~The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.~Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Adult non-transplant subjects with chronic hepatitis C virus
Description: For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.~In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Pediatric control subjects
Description: 2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
Study NCT02056054 — intervention group
Intervention type: OTHER
Intervention: Adult transplanted subjects with de novo autoimmune hepatitis
Description: 75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
Study NCT01531322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Study NCT04048265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
Study NCT04048265 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system
Study NCT04239105 — intervention group
Intervention type: DEVICE
Intervention: Microfluidic and Raman spectrum
Description: Detection of Circulating Tumor Cells
Study NCT02284620 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CFNB group
Description: CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
Study NCT02284620 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LWI group
Description: LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
Study NCT03364582 — intervention group
Intervention type: OTHER
Intervention: Observed dietary pattern
Description: No intervention will be used. This is an observational study with dietary patterns as main exposure
Study NCT03039166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 7T
Study NCT03039166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI 7T
Study NCT03039166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI 3 T
Study NCT03039166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI 3 T
Study NCT03039166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02207998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Homeopathic complex and physiotherapy
Description: Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
Study NCT02207998 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and physiotherapy
Description: Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
Study NCT01733966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secnidazole, ciprofloxacine
Description: 2g of microgranules of secnidazole. a single dose per day during 3 days.~1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)
Study NCT01733966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanic Acid
Description: 3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)